Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

KNP 301

Next Previous
Drug Profile

KNP 301

Alternative Names: KNP-301

Latest Information Update: 19 May 2026

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Kanaph Therapeutics
  • Class Bispecific antibodies; Eye disorder therapies; Immunoglobulin Fc fragments; Recombinant fusion proteins
  • Mechanism of Action Complement C3b inactivator protein inhibitors; Vascular endothelial growth factors inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Eye disorders

Most Recent Events

  • 27 Apr 2026 Preclinical trials in Eye disorders in South Korea (Parenteral) prior to April 2026 (Kanaph Therapeutics pipeline, April 2026)
  • 27 Apr 2026 Preclinical development for the treatment of dry age-related macular degeneration, wet age-related macular degeneration, diabetic macular oedema is ongoing in South Korea (Kanaph Therapeutics pipeline, April 2026)
  • 28 Jan 2024 No recent reports of development identified for preclinical development in Diabetic-macular-oedema in South Korea (Parenteral)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top